PET and PET/CT imaging: What clinicians need to know

Cleveland Clinic Journal of Medicine

Volumn 73, Issue 12, 2006, Pages 1075-1087

  Bybel, Bohdan ^a   Brunken, Richard C ^a   Shah, Shetal N ^a   Wu, Guiyun ^a   Turbiner, Elliott ^a   Neumann, Donald R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3 METHYLSPIPERONE C 11; 6 FLUORODOPA F 18; ACETIC ACID C 11; ANTINEOPLASTIC AGENT; ARGININE GLYCINE ASPARTIC ACID F 18; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROESTRADIOL F 18; FLUOROTHYMIDINE F 18; IODINE 124; LIPOCORTIN 5 F 18; METHIONINE C 11; RACLOPRIDE C 11; RUBIDIUM 82; TECHNETIUM 94M; THALLIUM 201; TRACER; TYROSINE C 11;

ADENOCARCINOMA; ALZHEIMER DISEASE; BENIGN TUMOR; BRAIN METASTASIS; BRAIN TUMOR; BREAST CANCER; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CARDIOLOGY; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ELECTROENCEPHALOGRAPHY; EPILEPSY; ESOPHAGUS CANCER; GLUCOSE METABOLISM; HEAD AND NECK CARCINOMA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE PERFUSION; HEART MUSCLE REVASCULARIZATION; HUMAN; LIVER METASTASIS; LUNG CANCER; LUNG NODULE; LYMPH NODE METASTASIS; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; META ANALYSIS; MINIMAL RESIDUAL DISEASE; MYOCARDIAL HIBERNATION; NEUROLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; PHARMACOLOGIC STRESS TESTING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION NECROSIS; REIMBURSEMENT; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; THYROID CANCER;

COIN LESION, PULMONARY; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33845350583     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.73.12.1075     Document Type: Review

References (55)

1. Surti S, Karp JS, Kinahan PE. PET instrumentation. Radiol Clin North Am 2004; 42:1003-1016.
2. Warburg O. On the origin of cancer cells. Science 1956; 123:309-314.
3. Ost D, Fein AM, Feinsilver SH. The solitary pulmonary nodule. N Engl J Med 2003; 348:2535-2542.
4. Erasmus JJ, Connolly JE, McAdams HP Roggli VL. Solitary pulmonary nodules: part I. Morphologic evaluation for differentiation of benign and malignant lesions. Radiographics 2000; 20:43-58.
5. Patz EF Jr, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993; 188:487-490.
6. 18F-FDG uptake below the Standardized uptake value of 2.5. J Nucl Med 2006; 47:426-431.
7. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001; 285:914-924.
8. Goldsmith SJ, Kostakoglu L. Role of nuclear medicine in the evaluation of the solitary pulmonary nodule. Semin Ultrasound CT MR 2000; 21:129-138.
9. Lee J, Aronchick JM, Alavi A. Accuracy of F-18 fluorodeoxyglucose positron emission tomography for the evaluation of malignancy in patients presenting with new lung abnormalities: a retrospective review. Chest 2001; 120:1791-1797.
10. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35:1647-1649.
11. Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998; 39:1016-1020.
12. Whyte RI. Advances in the staging of intrathoracic malignancies. World J Surg 2001; 25:167-173.
13. Bunyaviroch T, Coleman RE. PET evaluation of lung cancer. J Nucl Med 2006, 47:451-469.
14. Lardinois D. New horizons in staging for non-small-cell lung cancer. J Clin Oncol 2006; 24:1785-1787.
15. Ahuja V, Coleman RE, Herndon J, Patz EF Jr. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998; 83:918-924.
16. Mavi A, Lakhani P. Zhuang H, Gupta NC, Alavi A. Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer. Radiol Clin North Am 2005; 43:1-21.
17. Patz EF Jr, Lowe VJ, Goodman PC, Herndon J. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest 1995; 108:1617-1621.
18. Birim O, Kappetein AP, Stijnen T, Bogers AJ. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg 2005; 79:375-382.
19. Weder W, Schmid RA, Bruchhaus H, Hillinger S, von Schulthess GK, Steinert HC. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998; 66:886-892.
20. Erasmus JJ, Patz EF Jr, McAdams HP, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997; 168:1357-1360.
21. Blake MA, Slattery JM, Kalra MK, et al. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy-initial experience. Radiology 2006; 238:970-977.
22. Kolesnikov-Gauthier H, Levy E, Merlet P, et al. FDG PET in patients with cancer of an unknown primary. Nucl Med Commun 2005; 26:1059-1066.
23. Hainsworth JD, Greco FA. Management of patients with cancer of unknown primary site. Oncology (Williston Park) 2000; 14:563-574; discussion 574-579.
24. Bohuslavizki KH, Klutmann S, Kroger S, et al. FDG PET detection of unknown primary tumors. J Nucl Med 2000; 41:816-822.
25. Delgado-Bolton RC, Fernandez-Perez C, Gonzalez-Mate A, Carreras JL. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 2003; 44:1301-1314.
26. Flamen P, Stroobants S, Van Cutsem E, et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol 1999; 17:894-901.
27. Bipat S, van Leeuwen MS, Comans EF, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis - meta-analysis. Radiology 2005; 237:123-131.
28. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology 2006; 238:405-422.
29. Kim JH, Czernin J, Allen-Auerbach MS, et al. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med 2005; 46:587-595.
30. Fukui MB, Blodgett TM, Snyderman CH, et al. Combined PET-CT in the head and neck: part 2. Diagnostic uses and pitfalls of oncologic imaging. Radiographics 2005; 25:913-930.
31. Therasse P, Arbuck SG, Eisenhauer EA. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
32. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002; 43:1018-1027.
33. Wieder HA, Brucher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004; 22:900-908.
34. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003; 21:4604-4610.
35. Weber WA, Petersen V, Schmidt B. et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003; 21:2651-2657.
36. Brun E, Kjellen E, Tennnvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 2002; 24:127-135.
37. Surbone A, Longo DL, DeVita VT Jr, et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. J Clin Oncol 1988; 6:1832-1837.
38. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94:429-433.
39. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91:4464-4471.
40. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F)FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19:414-419.
41. Greven KM, Williams DW 3rd, McGuirt WF Sr, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 2001; 23:942-946.
42. Shaw LI, Iskandrian AE. Prognostic value of gated myocardial perfusion SPECT. J Nucl Cardiol 2004; 11:171-185.
43. Machac J. Cardiac positron emission tomography imaging. Semin Nucl Med 2005; 35:17-36.
44. Bateman TM, Heller GV, McGhie Al, et al. Diagnostic accuracy of rest/ stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol 2006, 13:24-33.
45. Go RT, MacIntyre WJ, Chen EQ, Cook SA, Neumann DR, Saha GB. Current status of the clinical applications of cardiac positron emission tomography. Radiol Clin North Am 1994; 32:501-519.
46. Klocke FJ, Baird MG, Lorell BH, et al; American College of Cardiology; American Heart Association; American Society for Nuclear Cardiology. ACC/ AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging - executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (ACC/AHA/ ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol 2003; 42:1318-1333.
47. Travin MI, Bergmann SR. Assessment of myocardial viability. Semin Nucl Med 2005; 35:2-16.
48. Allman KC, Shaw LI, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39:1151-1158.
49. Knuesel PR, Nanz D, Wyss C, et al. Characterization of dysfunctional myocardium by positron emission tomography and magnetic resonance: relation to functional outcome after revascularization. Circulation 2003; 108:1095-1100.
50. Silverman DH. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 2004; 45:594-607.
51. Heiss WD, Herholz K. Brain receptor imaging. J Nucl Med 2006; 47:302-312.
52. Herholz K, Heiss WD. Positron emission tomography in clinical neurology. Mol Imaging Biol 2004; 6:239-269.
53. Halliday S, Thrall JH. The business of PET/CT. AJR Am J Roentgenol 2005; 184(5 Suppl):S152-S155.
54. Bietendorf J. FDG PET reimbursement. J Nucl Med Technol 2004; 32:33-38.
55. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354:496-507.